Lung Cancer

dr sheikh pulmonologist :: Article Creator Zilpah Sheikh, MD Zilpah Sheikh, MD, attended Liaoning Medical University, P.R. China, in 2012, earning her bachelor's degree in medicine and surgery (MBBS) followed by her master's degree from the Crimean Federation, Russia, in 2016. She is a competent dermatologist skilled in diagnosing and treating a variety of skin conditions and co-morbidities associated with them. She has been actively involved in the creation of medical content. She is experienced in medical writing, reviewing, and designing content strategies for the general public and doctors. In her spare time, she likes to read, swim, and create colourful artwork while surrounded by a lot of stationary and, more recently, a little human. Saira Z Sheikh, MD Dr. Saira Sheikh is board certified in Internal Medicine, Rheumatology and Allergy/Immunology. She is Director of the UNC Rheumatology Lupus Clinic and Director of the Clinical Tria...

pulmonary and allergy associates doctors :: Article Creator Lung Health Mission The UAB Lung Health Center is committed to performing research that will benefit our patients and community, as well as furthering knowledge about mechanisms, therapies and behaviors that impact lung disease and its care, educating our patients and the public about lung disease, as well as enhancing the training of future specialists in pulmonary and critical care medicine and engaging in patient care initiatives of the Division of Pulmonary, Allergy, and Critical Care Medicine utilizing state-of-the-art, evidence-based disease management approaches. The Lung Health Center Pilot Program for Lung Research Application Guidelines Objectives UAB Lung Health Center physicians, academic scientists, nurses, and health educators collaborate with faculty in other UAB Departments, divisions, and schools to conduct research protocols, provide recruitment services, and colla...

symptoms of follicular lymphoma :: Article Creator Case Study: Relapsed Follicular Lymphoma A 58-year-old male with low-grade follicular lymphoma presents to oncology clinic with worsening bilateral cervical lymphadenopathy and fatigue over the past month. He was initially diagnosed 4 years ago, when he presented with bulky cervical and inguinal lymphadenopathy. He achieved a complete remission with 6 cycles of bendamustine and rituximab (BR), and has been monitored clinically since then. He has a history of hypertension, for which he takes lisinopril 10 mg daily. He states that he has been taking naps at the end of the work day for the past two weeks. The Bottom Line Patients with follicular lymphoma can often be monitored clinically, as the early intervention of chemotherapy or immunotherapy in asymptomatic low tumor burden patients has not demonstrated an overall survival benefit. Treatment is typically indicated when the patient develops ...

tnm definition :: Article Creator TNM Stages For Kidney Cancer The stage of a cancer tells you how big it is and how far it has spread. It helps your doctor decide which treatment you need. Doctors use a staging system called TNM. TNM stands for Tumour, Node and Metastasis. Doctors may also use a number staging system for kidney cancer. Stage 1 is the earliest stage and stage 4 is the most advanced. T stages of kidney cancer The T stage describes the size of the cancer. There are 4 T stages of kidney cancer. T1 is the smallest and T4 is the largest. T1 kidney cancer The cancer is 7cm across or smaller and is completely inside the kidney. T1 is divided into T1a and T1b depending on how big the cancer is: T1a means the cancer is 4cm across or smaller T1b means the cancer is between 4 and 7cm across If the cancer hasn't spread to the lymph nodes or other parts of the body, T1 kidney can...

early stages of lung cancer :: Article Creator How Robotic Technology Is Being Used In Lung Cancer Diagnosis Prev Next We have a health alert we want to bring you. We've done several reports about the dangers of lung cancer – which is the deadliest form of cancer in the United States. I spoke with a lung cancer survivor and her doctor about the technology that saved her life. Plus, I talked to her doctor about what you can do to prevent this deadly disease. "I got sick over New Year's and went to the emergency room and was in the hospital for six days with pneumonia," said Debra Haberstroh. While in the hospital, Haberstroh would receive a diagnosis that would change her life. "They found a spot on my lungs. Actually, they found several, but most of them were resolved except one," Haberstroh explained. TAMPA, Fla. — We have a health alert we want to bring you. We've done several reports about the d...

stage 4 lung cancer mayo clinic :: Article Creator FDA Approves New Drug For Non-Small Cell Lung Cancer With ROS1 Fusions Ingrid Adams, now 68, has been coping with metastatic lung cancer for more than a decade. Standard treatment — including chemotherapy and radiation therapy — kept her disease under control for a while, but the cancer continued to spread. Everything changed when she came to Memorial Sloan Kettering Cancer Center (MSK) in 2017 and was given the opportunity to participate in a phase 1 clinical trial (research study) for a targeted therapy called repotrectinib (Augtyro™). Six years later, the cancer has shrunk substantially, and her disease has remained stable ever since. The drug Ingrid was given was approved in November 2023 by the Food and Drug Administration (FDA) to treat advanced non-small cell lung cancer with a ROS1 fusion. The approval was based on findings from the trial in which Ingrid was one of the very first patient...

stage iv nsclc prognosis :: Article Creator Futile Immunotherapy For Cancer Grows More Common Providing immunotherapy for patients with metastatic cancer that proves quickly terminal is increasing, with more than 1 in 14 immunotherapy treatments in 2019 initiated within 1 month of death, according to a large retrospective cohort study. Proportions of patients with metastatic disease who started immunotherapy within 1 month of death rose over the study periods (the time of FDA approval until 2019) from 0.8% to 4.3% for melanoma, 0.9% to 3.2% for non-small cell lung cancer (NSCLC), and 0.5% to 2.6% for kidney cell carcinoma. By 2019, these end-of-life–initiated treatments represented 7.3% of all immunotherapy treatments, reported Sajid A. Khan, MD, of the Yale School of Medicine in New Haven, Connecticut, and colleagues. Moreover, the study showed that this practice is more common at non-academic and lower-volume health care centers, and t...